Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Opening this morning

<< Previous

Bullboard Posts

Next >>

Comment by SeeDonRunon Jan 27, 2022 2:49pm

111 Views

Post# 34367930

RE:RE:Opening this morning

PTBailey wrote: Can only speak for me personally. I am not swayed in my confidence by the day to day few cent changes. I am waiting to see where SP is by the time we are finished phase 1 and starting phase 2.

In the past there was always money issues, that is no longer a problem, so lets see what happens when whatever hurdles the company is having with Sentica are addressed to get phase 1 started.

I am not here for quick win, but would take it if it came, but plan to still be in this for up to min. of three years. If we are still here in three years I will cut my losses and get out.

Where are you getting this info from PT?

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market